Healio11h
IV edaravone may slow disease-progression milestones in ALS
Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...
Case study: Bartonella and Babesia co-infection in family associated with neurological illnesses
In a new case study, researchers from North Carolina State University found that a family suffering from illnesses that ...
University of Liverpool13d
Revealing insights into neurological disease treatment
Scientists from the University of Liverpool, and their global collaborators have highlighted the most effective treatments ...
Healio6h
FDA approves Onapgo for motor fluctuations in adults with Parkinson’s disease
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
infectiousdiseaseadvisor.com4d
Does Age Predict Severity of Neurologic Manifestations of “Long COVID?”
Compared with adults aged 65 and older, those aged 18 to 64 are more affected by long COVID neurologic symptoms.
BioSpace7d
Atalanta Gets $97 Million Series B to Target Neurological Disorders With RNAi
The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...
Georgia reports first case of 'zombie deer disease' | What to know
ATLANTA — The Georgia Department of Natural Resources (DNR) has confirmed the state's first case of Chronic Wasting Disease ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...